Intranasal tranexamic acid for the treatment of hereditary hemorrhagic telangiectasia: a case report and review of treatment options.

Abstract

Hereditary hemorrhagic telangiectasia (HHT) is an autosomal-dominant disorder. The disease has been formally characterized with epistaxis, cutaneous and mucosal telangiectases, a first-degree relative with HHT, and visceral lesions such as arteriovenous malformations (AVMs). Hereditary hemorrhagic telangiectasia has been underreported for many years. Wider recognition of this disorder in recent years has prompted researchers and physicians to recognize milder cases and focus on earlier treatment. This article highlights different treatments used to control epistaxis and screen for other complications associated with HHT.

• Authors: Brigitte A Flanagan, Chris Collins, Sylvia Parra
• Journal: Cutis (Cutis) Vol. 89 Issue 2 Pg. 69-72 (Feb 2012) ISSN: 0011-4162 [Print] United States
• PMID: 22474728 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antifibrinolytic Agents
• Tranexamic Acid

Topics

• Administration, Intranasal
• Antifibrinolytic Agents (administration & dosage, therapeutic use)
• Epistaxis (drug therapy, etiology)
• Female
• Humans
• Middle Aged
• Telangiectasia, Hereditary Hemorrhagic (drug therapy, physiopathology)
• Tranexamic Acid (administration & dosage, therapeutic use)
• Treatment Outcome